Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: Long-term results

Authors

Bruce D Cheson, Center for Cancer and Blood Disorders, Bethesda
Nancy L Bartlett, Washington University School of Medicine in St. Louis
Betsy Knopf, Mayo Clinic
Hun J Lee, University of Texas MD Anderson Cancer Center
Ranjana H Advani, Stanford University
Beth Christian, The Ohio State University
Catherine S Diefenbach, New York University
Tatyana A Feldman, Hackensack University Medical Center
Stephen M Ansell, Mayo Clinic

Journal

Blood Advances

Publication Date

8-12-2025

Volume

9

Issue

15

First Page

3750

Last Page

3753

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2025016470

Rights and Permissions

Cheson BD, Bartlett NL, Knopf B, Lee HJ, Advani RH, Christian B, Diefenbach CS, Feldman TA, Ansell SM. Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results. Blood Adv. 2025 Aug 12;9(15):3750-3753. doi: 10.1182/bloodadvances.2025016470. © 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Cheson, Bruce D; Bartlett, Nancy L; Knopf, Betsy; Lee, Hun J; Advani, Ranjana H; Christian, Beth; Diefenbach, Catherine S; Feldman, Tatyana A; and Ansell, Stephen M, "Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: Long-term results." Blood Advances. 9, 15. 3750 - 3753. (2025).
https://digitalcommons.wustl.edu/oa_4/6413